Bringing hepatitis B screening closer to migrant communities
A pilot program using mobile clinics to provide hepatitis B screening to migrant communities can address a practical gap in preventive care. People may understand the value of testing but still face language barriers, transport costs, unfamiliar health systems, work commitments, or concern about stigma. Taking services into trusted community settings can make the first step easier.
Hepatitis B is a viral infection that may remain without symptoms for years while gradually affecting the liver. Early diagnosis gives people access to monitoring, antiviral treatment when appropriate, vaccination for household contacts, and advice that can reduce transmission. A well-designed outreach model should therefore connect screening with clear follow-up rather than treating a test result as the end of care.
For Queensland health services and research partners, the pilot also offers a way to test how clinical innovation can work in real-world settings. Brisbane Diamantina Health Partners provides a useful health partnership network for connecting researchers, universities, clinicians, community organisations, and people with lived experience around this kind of translational work.
Why mobile screening matters
Migrant communities are diverse, and hepatitis B prevalence varies according to country of birth, migration history, vaccination access, and family health patterns. Some people may have acquired the infection at birth or during early childhood, when chronic infection is more likely. A universal, respectful offer of testing can be more effective than relying on people to recognise symptoms or request screening themselves.
A mobile clinic can operate at community centres, cultural festivals, places of worship, language schools, workplaces, and settlement services. Flexible opening hours and walk-in appointments may help people who cannot attend a hospital or general practice during business hours. The physical setting matters too: a familiar location can reduce anxiety and create opportunities for conversations about liver health, vaccination, and family testing.
Designing the pilot around trust
Trust should shape the service before the first vehicle arrives. Community leaders, multicultural health workers, migrant resource centres, primary care providers, and hepatitis organisations can help identify suitable locations and explain what screening involves. Their input can also guide the language used in consent materials, appointment reminders, and results communication.
Interpreters and bilingual workers should be part of the core team rather than an optional addition. Staff need training in culturally safe communication, confidentiality, trauma-informed care, and the difference between hepatitis B and hepatitis C. Explaining that a positive screening result is manageable and does not define a person’s identity can help reduce fear and stigma.
What the mobile clinic should provide
Screening usually begins with a blood test for hepatitis B surface antigen, with additional markers helping clinicians understand immunity and previous exposure. Depending on the clinical pathway, testing may also include liver function assessment and screening for other blood-borne viruses. A nurse, doctor, or trained health professional should explain the process in plain language and record consent appropriately.
The clinic needs a reliable system for delivering results and arranging confirmatory assessment. People with a positive result may require repeat testing, liver health review, viral load testing, imaging, or referral to a specialist or experienced general practitioner. People who are not immune should receive information about hepatitis B vaccination, including where and how to access a complete vaccine course.
| Pilot element | Practical approach | Measure of success |
|---|---|---|
| Community access | Set up at trusted locations with evening or weekend sessions | Number and diversity of attendees |
| Language support | Use interpreters and translated information | Participant-reported understanding |
| Clinical testing | Offer consented blood testing with clear explanations | Screening completion rate |
| Results pathway | Contact participants privately and promptly | Proportion receiving results |
| Ongoing care | Refer positive cases and support vaccination | Confirmed follow-up within an agreed timeframe |
| Quality and safety | Use secure records, trained staff, and clinical oversight | Data completeness and adverse-event monitoring |
Measuring outcomes beyond attendance
A strong evaluation should track more than the number of tests completed. Useful measures include the proportion of participants who receive their results, the number referred for follow-up, vaccination uptake among people without immunity, and the time from screening to clinical review. The pilot can also monitor whether participants feel respected, informed, and confident about their next steps.
Researchers should collect demographic information carefully and transparently. Country of birth, preferred language, age group, gender, and access needs may reveal which groups are being reached and which remain underserved. Data governance must protect privacy, particularly for people concerned about immigration status, employment, family disclosure, or discrimination. Personal health information should never be shared with unrelated agencies.
Qualitative interviews and community feedback can explain why the service succeeds or falls short. A participant may describe transport, childcare, fear, or previous negative experiences with healthcare that would not appear in a numerical dataset. Combining outcome data with these accounts creates a more useful picture of access and acceptability.
Moving from pilot evidence to routine care
The transition from a successful trial service to standard practice requires more than positive attendance figures. Health leaders need evidence about cost, workforce requirements, laboratory turnaround times, referral capacity, and whether mobile screening complements existing primary care rather than duplicating it. Clear responsibilities between the outreach team and receiving clinicians are essential.
This is where research into routine care becomes relevant. Translation involves adapting an intervention to local systems, reviewing its safety and effectiveness, and building the funding, governance, and workforce arrangements needed for continuation. A hepatitis B pilot should be designed with that future pathway in mind from the beginning.
The model may eventually support broader liver health services, including hepatitis C testing, vaccination catch-up, alcohol-related liver disease education, and referral for chronic disease care. Expansion should follow evidence and community priorities, not simply add more services to a mobile van without sufficient staff or follow-up capacity.
Building an equitable care pathway
Equity depends on what happens after the screening event. A person who receives a positive result should not be left to navigate specialist care alone, especially if they have limited English, unstable housing, financial pressure, or no regular doctor. Patient navigators can provide reminders, explain referrals, help with transport, and support communication between services.
Primary care practices near participating communities can strengthen the pathway by accepting referrals and offering culturally safe appointments. Hospitals, pathology providers, universities, and community organisations can contribute different capabilities while sharing agreed protocols. Research governance and ethics review should ensure that participants are partners in the work, not merely sources of data.
Health translation is strongest when clinical knowledge is linked to human experience. The work of individual researchers, such as the focus on better outcomes described in this researcher profile, reflects the broader principle that evidence must remain connected to patients and communities.
Priorities for a safe and useful pilot
- Co-design the service with migrant community representatives before selecting locations or languages.
- Pair every screening offer with a documented results, referral, and vaccination pathway.
- Train staff in hepatitis B knowledge, interpreting practice, privacy, and culturally safe care.
- Evaluate reach, participant experience, clinical follow-up, cost, and unintended barriers.
- Publish transparent findings so successful approaches can be adapted across Queensland.
A mobile clinic can bring hepatitis B testing closer to people who have been missed by conventional services, but its lasting value will depend on continuity, trust, and evidence. By linking community engagement with clinical expertise, ethical governance, and measurable follow-up, Queensland partners can turn a focused pilot into a stronger model for preventive health. Organizations interested in developing or evaluating this approach can connect with Brisbane Diamantina Health Partners to build the partnerships needed for responsible implementation.
